Aberrant DNA methylation in ES cells

Guy Ludwig, Deborah Nejman, Merav Hecht, Shari Orlanski, Monther Abu-Remaileh, Ofra Yanuka, Oded Sandler, Amichai Marx, Douglas Roberts, Nissim Benvenisty, Yehudit Bergman, Monica Mendelsohn, Howard Cedar

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Both mouse and human embryonic stem cells can be differentiated in vitro to produce a variety of somatic cell types. Using a new developmental tracing approach, we show that these cells are subject to massive aberrant CpG island de novo methylation that is exacerbated by differentiation in vitro. Bioinformatics analysis indicates that there are two distinct forms of abnormal de novo methylation, global as opposed to targeted, and in each case the resulting pattern is determined by molecular rules correlated with local pre-existing histone modification profiles. Since much of the abnormal methylation generated in vitro appears to be stably maintained, this modification may inhibit normal differentiation and could predispose to cancer if cells are used for replacement therapy. Excess CpG island methylation is also observed in normal placenta, suggesting that this process may be governed by an inherent program.

Original languageAmerican English
Article numbere96090
JournalPLoS ONE
Issue number5
StatePublished - 22 May 2014


Dive into the research topics of 'Aberrant DNA methylation in ES cells'. Together they form a unique fingerprint.

Cite this